HARP Mindfulness Study for Cardiovascular Diseases

This study is exploring if adding extra support helps people with heart disease or heart disease risk factors manage stress, anxiety, and depression. It's testing two types of support: monthly "Booster Mindfulness Sessions" and a "Website Support" tool. These are added to an 8-week program called MBCT-T, which combines mindfulness and cognitive-behavioral therapy. You could join if you are 18 or older and have ischemic heart disease (a type of heart disease) without recent hospitalizations, or if you have risk factors for heart disease. The study will measure your stress, depression, and anxiety levels at the beginning, after the 8-week program, and again six months later. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 160 participants. It uses a specific design to see if extra support improves the main mindfulness program.
What's involved
You would participate in an 8-week group-based program, with weekly 1-hour sessions. Some participants will also have monthly 1-hour booster sessions for 4 months and access to a study website.
Compensation
Not stated in the trial record.
Follow-up
Your stress, depression, and anxiety levels will be measured at the beginning, after the 8-week program (Month 2), and again at Month 6.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05841784

HARP Mindfulness Study

Recruiting
NAAges 18+InterventionalSupportive care
NYU Langone Health
~160 participants
Updated 2026-04-17 on ClinicalTrials.gov
What's tested:MBCT-TBooster Mindfulness SessionsWebsite Support

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite Score of 3 Questionnaires: Perceived Stress Scale 10-item Version (PSS-10); Patient Health Questionnaire 9-Item Version (PHQ-9); and Generalized Anxiety Disorder Questionnaire 7-Item Version (GAD-7) at Baseline
Measured over Baseline
+2 more outcomes measured
Cardiovascular Diseases
1 sites across 1 states
New York1
  • Tanya Spruill, PhD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients meeting one of the following criteria:
Has a diagnosis of ischemic heart disease (ICD-10 codes I20 - I25) with no cardiac hospitalizations in the past 6 months
Has cardiovascular disease risk factors without meeting a diagnosis of ischemic heart disease or having a cardiovascular disease event (heart attack, stroke, heart failure, and/or unstable angina). Cardiovascular disease risk factors include hypertensive diseases (ICD-10 codes I10 - I11, I15 - I16), diabetes (E8 - E13), and/or hyperlipidemia (E78.0 - E78.5, E78.9)
Patients meeting one or more of the following criteria at baseline:
Elevated stress (PSS-10 score ≥15)
Mild to moderate depressive symptoms (PHQ-9 score between 5-14)
Mild or greater anxiety (GAD-7 score ≥5)
Willing to provide informed consent and comply with all aspects of the protocol
Able to read and communicate in English

Exclusion

Active suicidal ideation
History of, or current diagnosis of, psychosis
Significant cognitive impairment (noted in the EHR or evident during screening)
Significant hearing loss
Current participation in another behavioral clinical trial
Has received the MBCT-T intervention in a previous clinical trial.
  • Composite Score of 3 Questionnaires: Perceived Stress Scale 10-item Version (PSS-10); Patient Health Questionnaire 9-Item Version (PHQ-9); and Generalized Anxiety Disorder Questionnaire 7-Item Version (GAD-7) at BaselineBaseline

    Composite score of 3 questionnaires. The total composite score is the sum of scores from the questionnaires and ranges from 0 to 88; lower scores indicate greater overall health. PSS-10 measures perceived stress over the past month. Items rated on a 5-point scale ranging from 0 (never) to 4 (very often). Total scores range from 0-40; higher scores indicate greater levels of perceived stress. PHQ-9 assesses depressive symptoms in the past two weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. GAD-7 measures anxiety symptoms in the past 2 weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-21 with recommended cutoffs for mild (5-9), moderate (10-14), and severe (15-21) anxiety.

  • Composite Score of 3 Questionnaires: PSS-10; PHQ-9; and GAD-7 at Post-InterventionMonth 2

    Composite score of 3 questionnaires. The total composite score is the sum of scores from the questionnaires and ranges from 0 to 88; lower scores indicate greater overall health. PSS-10 measures perceived stress over the past month. Items rated on a 5-point scale ranging from 0 (never) to 4 (very often). Total scores range from 0-40; higher scores indicate greater levels of perceived stress. PHQ-9 assesses depressive symptoms in the past two weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. GAD-7 measures anxiety symptoms in the past 2 weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-21 with recommended cutoffs for mild (5-9), moderate (10-14), and severe (15-21) anxiety.

  • Composite Score of 3 Questionnaires: PSS-10; PHQ-9; and GAD-7 at Follow-UpMonth 6

    Composite score of 3 questionnaires. The total composite score is the sum of scores from the questionnaires and ranges from 0 to 88; lower scores indicate greater overall health. PSS-10 measures perceived stress over the past month. Items rated on a 5-point scale ranging from 0 (never) to 4 (very often). Total scores range from 0-40; higher scores indicate greater levels of perceived stress. PHQ-9 assesses depressive symptoms in the past two weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27 with recommended cutoffs for mild (5-9), moderate (10-14), moderately severe (15-19) and severe (≥20) depressive symptoms. GAD-7 measures anxiety symptoms in the past 2 weeks. Items rated on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0-21 with recommended cutoffs for mild (5-9), moderate (10-14), and severe (15-21) anxiety.